Endocrine Connections · 2020 · 16 citations · 38 references
MedicineOncologyPathologyMolecular OncologyNeoplasiaTumor MicroenvironmentCancer BiomarkersCancer Molecular PathologyEpithelial-mesenchymal TransitionEpithelial-to-mesenchymal TransitionThyroid CancerTumor MarkersDisease-free Survival AssessmentEpithelial-mesenchymal Transition In CancerEpithelial-mesenchymal Transition MarkersKaplan-meier Survival EstimatesProgrammed Cell Death Ligand 1 RegulationProgrammed Death-ligand 1 BiomarkerProgrammed Death-ligand 1 SignalingThyroid Cancer Pathology
Programmed cell death-ligand 1 (PD-L1) has recently been shown to play a role in the regulation of epithelial-to-mesenchymal transition (EMT); however, the relationship between PD-L1 expression, EMT and the inflammatory tumour microenvironment has yet to be investigated in thyroid cancer. To address this issue, we examined the expression of CD8, PD-L1 and the EMT markers E-cadherin and vimentin in a cohort of 74 papillary thyroid cancer (PTC) patients and investigated the association of these with clinicopathologic characteristics and disease-free survival (DFS). The relationship between PD-L1 and EMT was further examined in three thyroid cancer cell lines via Western blot and live cell imaging. In order to expand our in vitro findings, the normalised gene expression profiles of 516 thyroid cancer patients were retrieved and analysed from The Cancer Genome Atlas (TCGA). PD-L1 positivity was significantly higher in PTC patients exhibiting a mesenchymal phenotype (P = 0.012). Kaplan-Meier analysis revealed that PD-L1 (P = 0.045), CD8 (P = 0.038) and EMT status (P = 0.038) were all significant predictors for DFS. Sub-analysis confirmed that the poorest DFS was evident in PD-L1 positive patients with EMT features and negative CD8 expression (P < 0.0001). IFN-γ treatment induced upregulation of PD-L1 and significantly promoted an EMT phenotype in two thyroid cancer cell lines. Our findings suggest that PD-L1 signalling may play a role in stimulating EMT in thyroid cancer. EMT, CD8 and PD-L1 expression may serve as valuable predictive biomarkers in patients with PTC.
38
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers, Jared Lunceford, Michael Nebozhyn et al. · Journal of Clinical Investigation · 2017 · 3.9K citations · Full text
Medicine, Immunology, Oncology +17
Jonathan E. Rosenberg, Jean Hoffman‐Censits, Tom Powles et al. · The Lancet · 2016 · 3.7K citations
Medicine, Oncology, Pharmacotherapy +13
Drug delivery with carbon nanotubes for in vivo cancer treatment
Zhuang Liu, Kai Chen, Corrine R. Davis et al. · PubMed · 2008 · 2.3K citations · Full text
Pharmacy, Oncology, Pharmacology +17